Short from 103.5 but expect some further buying could see some profit taking by institutions over coming months.
- $1bn short interest
- 189.82 price to book ratio shows the inflated share price.
- 1.96 beta
- Considering its returned 549.33% in the past year and is already up 70.81% YTD and is 97.28% institutionally owned is of concern if earnings miss estimates/drugs fail and the institutions start profit taking.
- Nektar relies heavily on partners such as AstraZeneca and Shire for revenues in the form of equity investment, collaboration milestone payments and license.
- Given the royalty opportunity associated with Movantik and Adynovate with AstraZeneca and Shire.
- The level of sales achieved by NYSE:AZN and LSE:SHP will have a significant impact on NKTR financial condition over the next few years. If these drugs fail to achieve success commercially or if the candidates in the development stages fail to generate positive outcomes sufficient to regulatory approval in major markets it could significantly affect the share price and companies access to capital necessary for its R&D.
- Gaining approval for candidates has become more difficult with a tightening regulatory environment.
- Return on Equity -156.85%
- Debt/Capital - 73.63%
- Earning Yield (1.29%)
NeroTree Capital rates Nektar Therapeutics as a SELL with a price target of $80 over the next 52w.
- $1bn short interest
- 189.82 price to book ratio shows the inflated share price.
- 1.96 beta
- Considering its returned 549.33% in the past year and is already up 70.81% YTD and is 97.28% institutionally owned is of concern if earnings miss estimates/drugs fail and the institutions start profit taking.
- Nektar relies heavily on partners such as AstraZeneca and Shire for revenues in the form of equity investment, collaboration milestone payments and license.
- Given the royalty opportunity associated with Movantik and Adynovate with AstraZeneca and Shire.
- The level of sales achieved by NYSE:AZN and LSE:SHP will have a significant impact on NKTR financial condition over the next few years. If these drugs fail to achieve success commercially or if the candidates in the development stages fail to generate positive outcomes sufficient to regulatory approval in major markets it could significantly affect the share price and companies access to capital necessary for its R&D.
- Gaining approval for candidates has become more difficult with a tightening regulatory environment.
- Return on Equity -156.85%
- Debt/Capital - 73.63%
- Earning Yield (1.29%)
NeroTree Capital rates Nektar Therapeutics as a SELL with a price target of $80 over the next 52w.
Trade closed: target reached:
Took profit at 82.64 - (+20.15%)